A new space in the immunotherapy market
Spin-off from the Pasteur Institute, DIACCURATE is opening a new space in the booming market segment of immunotherapy: trans CD4 immunotherapy. By blocking a molecular mechanism leading to CD4 anergy, DIACCURATE aims to restore the CD4 T-cells’ ability to fight microbial infections and cancers.
Today DIACCURATE is conducting proprietary development programs in disease indications with partial or total CD4 immunodeficiency. A phase I/II multi-center trial is already planned in HIV for the most advanced product of the company, the anti-PLA2G1B enzyme drug candidate; a “sole in class antibody” that could achieve for the very first time the functional cure of HIV patients.
DIACCURATE was founded by Prof. Jacques THÈZE, an international leading authority in the fields of CD4 biology and HIV infection and its former student, Dr. Philippe POULETTY, who since then has pioneered the development of biotechnology and co-founded Truffle Capital of which he is now the Life Science General Manager.
Based in Paris, France, at the Pasteur Institute, the company is supported by an experienced management team and a world class academic network committed to make CD4 trans immunotherapy a new therapeutic standard in infections and cancers.
Founders
Prof. Jacques THÈZE, MD, PhD, CEO, CSO
-
Former Prof and Head dpt Human Immunology at Institut Pasteur
-
Post doc fellow Harvard Medical School (B. Benacerraf)
-
> 250 scientific and medical publications
-
WHO adviser “New vaccine program”
-
Sanofi Co. adviser ” Cytokines and immunotherapy program”
-
Corresponding member of the French National Academy of Medicine
Dr. Philippe POULETTY, MD, Chairman
-
Co-founder & Life Science General Manager of Truffle Capital
-
Postdoctoral fellow Stanford University
-
SangStat co-founder (acquired by Genzyme $600 million)
-
29 patents in biotechnology
-
Member of the board of directors of 12 European biotechs and medtechs
-
Honorary President & founder of France Biotech
-
Former Vice-President of EuropaBio
Leadership team
Leadership team
José DA GLORIA,
Deputy CEO and CFO
-
CFO at Vexim
-
Former Head of Finance at Cloudwatt
Jérôme TIOLLIER, PhD
Senior Consultant Development
-
Chairman of OFU
-
Former EVP & Chief Dev. Officer at Innate Pharma (2001-2018)
Dr. Jean Pierre ROUTY, MD
Senior Consultant Clinical
-
Professor and Research, Director at McGill University Health Centre
Bernard MALISSEN, PhD, Senior Consultant Scientific Affairs
-
Director of CIPHE
-
Member of the French Academy of Science
Scientific Board
A Pasteur Institute’s heritage
From the identification of the etiologic agent of AIDS to the discovery of blood molecular driver of CD4 immunodeficiency, Diaccurate is the fruit of over 30 years of research and innovation done by the Pasteur Institute in Paris.
